Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes

NCT03018028 · Completed

Last updated 2026-05-28

This clinical trial tested different doses of oral semaglutide, a placebo, and liraglutide in adults with type 2 diabetes to see how they affect blood sugar levels over 26 weeks.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 243 people

Who can join Ages 20+ · all sexes

Timeline Started 2017-01 · est. completion 2018-08

Where 16 sites · Japan

What this study is testing ClinicalTrials.gov NCT03018028 ↗

Description as written by the study sponsor.

This trial is conducted in Asia. The aim of this trial is to investigate the dose-response relationship of once-daily dosing of three dose levels (3, 7 and 14 mg) of oral semaglutide versus placebo as monotherapy on glycaemic control in Japanese subjects with type 2 diabetes mellitus

Treatments tested

Semaglutide Drug

Oral administration once daily
Placebo Drug

Oral administration once daily
Liraglutide Drug

Subcutaneous (s.c., under the skin) injection once daily

Main thing measured	Change in HbA1c (Week 26)
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Diabetes Mellitus, Type 2
GLP-1 drugs	semaglutide, liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03018028 ↗